Research progress in immune-related liver injury caused by immune checkpoint inhibitors

VernacularTitle:免疫检查点抑制剂致免疫相关肝损伤的研究进展
Author: Fenghui LI ¹ ; Tao WANG ; Fushuang HA ; Fei TANG ; Jing LIANG
Author Information

1. 天津市第三中心医院消化肝病科，天津市重症疾病体外生命支持重点实验室，天津市人工细胞工程技术研究中心，天津市肝胆疾病研究所，天津　300170
Keywords: Immune checkpoint inhibitors; Immune-related adverse events; Immune-mediated liver injury
From: International Journal of Biomedical Engineering 2023;46(2):169-174
CountryChina
Language:Chinese
Abstract: In recent years, immune checkpoint inhibitors (ICIs) have made great progress in the treatment of tumor patients, prolonging their survival. However, the expansion of immunity against tumors with ICIs may also cause an imbalance in immune tolerance, leading to immune-related adverse events (irAEs). Immune-mediated liver injury caused by ICIs (ILICI) is one of the more common types of irAEs. In this review paper, the definition, epidemiology, risk factors, pathogenesis, pathology, clinical manifestations, treatment, recurrence, and re-treatment of ILICI were summarized to provide a basis for clinical diagnosis and treatment.